BRASILIA (Reuters) – The Brazilian pharmaceutical company that will make Russia’s Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next ...

Batches of Russia’s Sputnik V Covid vaccine which were sent to Brazil carried a live version of the common cold virus, Brazil’s health regulator reported.

Health regulators in Brazil say that doses of Russia’s Sputnik V COVID-19 vaccine contain a cold-causing virus capable of replicating in human cells. The unintended presence of the virus in the ...

Brazil's drug regulator wasn't the first to flag apparent anomalies with Sputnik V vaccine doses, and scientists say their import ban seems prudent.

05/04/2021 Brazil has halted approval of Sputnik V, claiming that a vector virus in the vaccine was not inactive and could cause severe colds. Russia is denying the accusation.

Brazil's National Health Surveillance Agency (Anvisa) Friday approves, albeit with some restrictions, imports of Covaxin and Sputnik V doses for use in up to 1% of the country's population, it was ...

On July 3, ahead of the BRICS Summit, Sputnik Brasil gathered prominent experts and journalists from leading Brazilian and ...

Russia's Sputnik V COVID-19 vaccine has requested regulatory approval to launch Phase 3 trials in Brazil, Brazilian health regulator Anvisa said late on Tuesday.

Until now, only the AstraZeneca/Oxford shot and China's CoronaVac have been permitted in Brazil, the second-hardest-hit country after the US, with more than 226,000 deaths from COVID-19.

RIO DE JANEIRO (AP) — Brazil’s health regulator cited safety concerns while rejecting several states’ requests to import almost 30 million doses of Russia’s Sputnik V vaccine, prompting ...

BRASILIA (Reuters) – Brazil’s health regulator Anvisa lacks the information necessary to evaluate the safety and efficacy of Russia’s Sputnik V vaccine, the agency said in legal documents ...

The Brazilian pharmaceutical company that will make Russia's Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next at the latest, its Chief ...